AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
| Revenue (TTM) | $61.37B |
| Gross Profit (TTM) | $50.13B |
| EBITDA | $20.25B |
| Operating Margin | 23.50% |
| Return on Equity | 22.00% |
| Return on Assets | 8.21% |
| Revenue/Share (TTM) | $39.59 |
| Book Value | $32.43 |
| Price-to-Book | 5.19 |
| Price-to-Sales (TTM) | 4.18 |
| EV/Revenue | 4.726 |
| EV/EBITDA | 14.25 |
| Quarterly Earnings Growth (YoY) | 2.50% |
| Quarterly Revenue Growth (YoY) | 6.40% |
| Shares Outstanding | $1.55B |
| Float | $1.54B |
| % Insiders | 0.05% |
| % Institutions | 65.10% |
Volatility is currently expanding
AZN, RHHBY, PBYI and OLMA offer exposure to breast cancer drug sales growth, expanded treatment approvals and clinical milestones that could shape prospects.
Astrazeneca (AZN) closed the most recent trading day at $166.68, moving +2.87% from the previous trading session.
RBC Capital Markets has maintained its 'outperform' rating on AstraZeneca PLC (LSE:AZN, NYSE:AZN), the FTSE 100 pharmaceutical group, with a 14,500p target price, expecting a quiet third quarter before results on Friday 30 October. It forecasts third-quarter revenue of $16.3 billion, 1.8% above the consensus estimate of $16.0 billion, and core earnings per share (EPS) of $2.61, 0.8% ahead of the $2.59 consensus.
AstraZeneca PLC (AZN) Presents at American Society for Bone and Mineral Research (ASBMR) 2026 Annual Meeting Transcript
Astrazeneca NYSE: AZN presented Phase III data for efzimfotase alfa, an investigational enzyme replacement therapy for hypophosphatasia (HPP), at the American Society for Bone and Mineral Research annual meeting in Boston. The company said the therapy showed improvements in several measures of function, pain and fatigue in adolescents and adults, although the HICKORY trial did not meet its primary endpoint.
Citi has maintained its 'buy' rating on AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) with a target price of £186, arguing that detailed trial data for its rare disease drug efzimfotase alfa support a peak sales scenario almost double its current base case if the therapy secures broad adult approval in the US. The data, presented at the American Society for Bone and Mineral Research meeting, came from the Phase III HICKORY trial of the enzyme replacement therapy in patients with hypophosphatasia, a rare inherited bone disorder.
Jefferies maintained a 'buy' rating on AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the biopharmaceutical company, with a 17,500p price target, representing 46% potential upside from its 11,958p share price. The broker expects AstraZeneca to report third-quarter revenue about 1% ahead of the Visible Alpha consensus and core earnings before interest and tax at 3% above expectations.
In the latest trading session, Astrazeneca (AZN) closed at $158.61, marking a +1.33% move from the previous day.
Citi raised its target price for AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the FTSE 100 pharmaceutical company, to £186 from £178 and retained its 'buy' rating after recent clinical developments. The broker increased its peak sales forecast for tozorakimab to $7 billion and for SERENA-6 to $1.1 billion, more than offsetting the removal of its $1.7 billion forecast for SERENA-4.
AstraZeneca CEO Pascal Soriot told CNBC that Summit Therapeutics' lead drug could help power next-generation cancer combinations that could be the "future of cancer care." Soriot spoke exclusively with CNBC from the site of AstraZeneca's new more than $1 billion research and development facility in Kendall Square in Cambridge, Massachusetts.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on AZN and any ticker you trade — then tracks every position and per-strategy win rate.
